Anemia Associated With Chronic Kidney Disease (CKD)

Hematology
2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

On Market (1)

Approved therapies currently available

Akebia Therapeutics
VAFSEOApproved
vadadustat
Akebia Therapeutics
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]oral2024

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Akebia Therapeutics
Akebia TherapeuticsCAMBRIDGE, MA
1 program
1
1
VadadustatPhase 3Small Molecule1 trial
Active Trials
NCT04707768CompletedEst. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Akebia TherapeuticsVadadustat

Clinical Trials (1)

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Start: Jun 2021Est. completion: Jan 2023
Phase 3Completed

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space